Literature DB >> 6207137

Goblet cell density and vascularization during conjunctival transdifferentiation.

S C Tseng, L W Hirst, M Farazdaghi, W R Green.   

Abstract

After debridement of the entire corneal epithelium with n-heptanol, two groups of rabbit corneas were segregated according to the extent of corneal neovascularization. Using a new topographic goblet-cell counting method and routine histology, the authors have reexamined the process of conjunctival transdifferentiation and compared the changes of goblet-cell density and morphology between nonvascularized and vascularized groups for a follow-up period of 167 days. Analysis of the total goblet-cell density disclosed that no goblet cells appeared on the corneal surface during the entire period of reepithelialization. After that, two phases were identified with respect to goblet-cell density: phase I (day 0-17) and phase II (after day 17). In phase I, both groups had a similar surge of goblet cells, with the peak occurring between days 7 and 11, suggesting little correlation with vascularization. Morphologic studies indicated the presence of a prominent centripetal cellular migration. In phase II, the nonvascularized group showed a rapid decline in goblet-cell density, and as a result the morphologic transdifferentiation into a cornea-like epithelium was completed on day 43. The changes of goblet cells to a smaller size and the presence of a more acidic mucin in the centrifugal receding zone, suggested that transdifferentiation on nonvascularized corneas is a process involving changes of cellular differentiation. In contrast, the vascularized group maintained a high plateau of goblet-cell density and an epithelium with conjunctival characteristics until day 167. This result disclosed that retardation of conjunctival transdifferentiation by corneal vascularization was in phase II. The possible role of vascularization in the modulation of conjunctival transdifferentiation is discussed.

Entities:  

Mesh:

Year:  1984        PMID: 6207137

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  The ocular surface toxicity of paraquat.

Authors:  D McKeag; R Maini; H R Taylor
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

2.  Laser photocoagulation for corneal stromal vascularization.

Authors:  V S Nirankari
Journal:  Trans Am Ophthalmol Soc       Date:  1992

3.  Cultured corneal epithelia for ocular surface disease.

Authors:  I R Schwab
Journal:  Trans Am Ophthalmol Soc       Date:  1999

4.  Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris.

Authors:  T A Ciulla; M H Criswell; W J Snyder; W Small
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

5.  A traumatic cyst of the sclera.

Authors:  M Prost
Journal:  Int Ophthalmol       Date:  1991-07       Impact factor: 2.031

Review 6.  Concise review: immunological properties of ocular surface and importance of limbal stem cells for transplantation.

Authors:  Bakiah Shaharuddin; Sajjad Ahmad; Annette Meeson; Simi Ali
Journal:  Stem Cells Transl Med       Date:  2013-07-01       Impact factor: 6.940

Review 7.  Regulation and clinical implications of corneal epithelial stem cells.

Authors:  S C Tseng
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

8.  The conjunctiva in corneal epithelial wound healing.

Authors:  H S Dua
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

Review 9.  Corneal epithelial wound healing.

Authors:  H S Dua; J A Gomes; A Singh
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

Review 10.  [Dry eye disease as a complex dysregulation of the functional anatomy of the ocular surface. New concepts for understanding dry eye disease].

Authors:  E Knop; N Knop; H Brewitt
Journal:  Ophthalmologe       Date:  2003-11       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.